Pharmacogenetics and the development of personalized approaches for combination therapy in asthma.

ABSTRACT: Asthma is a common, chronic disease of the airways that is treated with a combination of different therapies. The combination of LABA and ICS therapy results in a synergistic interaction that is efficacious in improving asthma symptom control; however, genetic variation has the potential to alter therapeutic efficacy. Both agents mediate complex molecular pathways consisting of gene variation that has been investigated with the analysis of candidate genes in the β2-adrenergic receptor and glucocorticoid pathway. These pharmacogenetic studies have been limited to retrospective analyses of clinical trial cohorts and a small number of prospective, genotype-stratified trials. More recently, genome-wide association studies in combination with replication in additional cohorts and in vitro cell-

SUBMITTER: Miller SM 

PROVIDER: S-EPMC3878163 | biostudies-literature | 2013 Oct

REPOSITORIES: biostudies-literature